Rep. Cathy McMorris Rodgers

R

Washington – District 5


Leadership

Republican Leader

117th Congress

Chair

118th Congress

News & Announcements


Oct 24, 2024
Press Release

E&C Republicans Call for Transparency in Taxpayer-Funded Clinical Trial Results

Washington, D.C. — Republican Members of the House Energy and Commerce Committee issued the following statements regarding a report that results from a National Institutes of Health (NIH) funded research project are being withheld from the public due to political motives. “This is a clear example of the politicization of science at the expense of children. Research funded by taxpayer dollars through the NIH should be publicly disclosed regardless of the results, and Americans deserve access to the truth,” said Committee Chair Cathy McMorris Rodgers (R-WA) . “For a scientist to withhold findings deliberately because the findings don’t substantiate a preferred outcome further erodes public trust in the NIH and its programs. Our Committee will be launching an investigation into the matter.”  “These recent revelations are a great example of why Congress and the American people are demanding more transparency and accountability from the U.S. public health community,” said Subcommittee on Health Chair Brett Guthrie (R-KY) . “Not publishing the results of taxpayer-funded research in fear of political blowback not only further erodes trust in our public health institutions, but also fundamentally undermines the very nature of scientific research. Most importantly, failing to publish these results to protect one’s own political agenda puts vulnerable children at risk of serious self-harm. I call on the NIH to immediately suspend funding of this study and to immediately publish the study’s results for the American people to see for themselves.” “Delaying the publication of clinical trial studies, funded in part by the federal government, for fear that its findings would be ‘weaponized’ by those who are opposed to invasive transgender procedures in juveniles is irresponsible and inappropriate,” said Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) . “The American people should be allowed to follow the science even when it leads to a conclusion that the scientist doing the study doesn’t like.” “Puberty blockers and sex-change operations harm children, period. It’s outrageous for taxpayer-funded research to be hidden from the public, especially when it is being suppressed by a transgender advocate simply because the findings don’t fit their political agenda,” said Representative Diana Harshbarger (R-TN) . “This is a glaring example of why NIH must be reformed with measures like those initiated by Chair Rogers to ensure transparency, standards of objectivity, and the removal of conflicts of interest in federal taxpayer-funded scientific and medical research. The NIH must release the results of this taxpayer-funded study immediately.”  BACKGROUND : As reported in the New York Times , an NIH-funded researcher and vocal advocate for hormonal gender treatments on minors, who receives millions of dollars of taxpayer funding, is withholding the results of studies because they do not demonstrate clinical benefit of providing such treatments. The United States remains an outlier by providing hormonal-based therapies that delay puberty to minors for the purposes of gender transitioning, while many other developed nations are moving away from the practice. 



Oct 23, 2024
Press Release

E&C Republicans Release Report Detailing HHS’ Failed COVID-19 Public Relations Campaign

$900 million taxpayer dollars used to amplify the Biden-Harris administration’s flawed messaging on COVID-19 pandemic Washington, D.C. — In a new report , House Energy and Commerce Committee Republicans unveiled the failings of a $900 million COVID-19 public relations campaign, issued and overseen by the U.S. Department of Health and Human Services (HHS). It is the culmination of the Committee’s investigation , which was launched in April 2023. “While the Biden-Harris administration’s public health guidance led to prolonged closures of schools and businesses, the NIH was spending nearly a billion dollars of taxpayer money trying to manipulate Americans with advertisements—sometimes containing erroneous or unproven information. By overpromising what the COVID-19 vaccines could do—in direct contradiction of the FDA’s authorizations—and over emphasizing the virus’s risk to children and young adults, the Biden-Harris administration caused Americans to lose trust in the public health system,” said Committee Chair Cathy McMorris Rodgers (R-WA). “Our investigation also uncovered the extent to which public funding went to Big Tech companies to track and monitor Americans, underscoring the need for stronger online data privacy protections.” “I am proud to see this report uncover the truth behind the Biden-Harris administration’s use of $900 million of taxpayer funds to further their own political agenda that sowed distrust in our public health institutions, kept kids out of the classroom, and crushed local economies,” said Subcommittee on Health Chair Brett Guthrie (R-KY ). “American trust in the CDC is at an all time low because the Biden-Harris administration’s flawed pandemic messaging, and this report is the first step in holding CDC and other agencies to account for the harms caused throughout the pandemic and ensure these institutions are operating openly and transparently with the American public during future pandemics.”  “The entire premise of the Biden-Harris ‘Stop the Spread’ campaign was that if you got vaccinated for COVID-19, you could resume daily activities because they said vaccinated people would not spread the disease,” said Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) . “Despite lacking scientific basis, the administration bought into this CDC claim and misled the American public. As a result, vaccination coverage with other vaccines appears to have declined, I believe because of a growing distrust of information coming from our public health institutions.”  BACKGROUND :  The overall goal of this report is to understand why, with the extent of these resources, the HHS public relations campaign (Campaign) and the Biden-Harris administration’s response to the pandemic resulted in a collapse of trust in public health messaging.   Much of the scientific content directly featured in or alluded to in Campaign ads and other promotional material was drawn from CDC recommendations, guidance, and research, critical parts of which proved to be deeply flawed. The CDC’s errors and failures to update recommendations and guidance were reflected in the “We Can Do This” ads and promotional materials:  CDC’s guidance, which the Campaign relied on, went beyond the terms of FDA’s Emergency Use Authorization (EUA) to state, without evidence, that COVID vaccines were highly effective against transmission. This ultimately had a negative impact on vaccine confidence and the CDC’s credibility when proven untrue.   The CDC had inconsistent and flawed messaging about the effectiveness of masks.  The CDC consistently overstated the risk of COVID-19 to children. The CDC continues to recommend COVID-19 vaccines for all Americans ages six months and older, which has made the United States a global outlier in COVID-19 policy.  RECOMMENDATIONS :  Americans cannot afford another botched government response to a future pandemic. To prevent a recurrence of HHS’s failures in public relations management for the COVID-19 pandemic response and to strengthen the nation’s public health preparedness system, the Committee makes the following recommendations:  Congress should consider formally authorizing the CDC and clearly define the agency’s core mission.  HHS and its agencies should abide by the FDA’s product labeling guidelines. HHS and its agencies should be barred from promoting information regarding an FDA-regulated product that does not reflect the FDA-approved label. Congress should consider clarifying responsibility for evaluating the safety of vaccines and streamline existing reporting systems for capturing vaccine injuries and adverse reactions. HHS and its agencies should embrace a culture of transparency and accountability. The CDC and federal public health officials should not attempt to silence dissenting scientific opinions. HHS and its agencies should overhaul their website archival process to mimic that of prior White House administrations. CLICK HERE to read the full report and complete list of recommendations. 



Oct 21, 2024
Press Release

Bipartisan E&C Leaders Call on GAO to Review the DOE Isotope Program’s Work to Reduce Reliance on Russia

More than a decade has lapsed since the GAO’s last review Washington, D.C. —  In a new letter to the U.S. Government Accountability Office (GAO), bipartisan Energy and Commerce Leaders are requesting that the GAO conduct an extensive review of the Department of Energy’s (DOE) Isotope Program. Led by Committee Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr., (D-NJ) as well as Subcommittee on Energy, Climate, and Grid Security Chair Jeff Duncan (R-SC) and Ranking Member Diana DeGette (D-CO), the letter addresses concerns regarding U.S. dependence on Russia for isotopes and other materials critical to American national security, advanced manufacturing, and medicine, especially following Russia’s invasion of Ukraine. KEY LETTER EXCERPT: “The DOE Isotope Program has been working for at least a decade to shore up domestic isotope development and free the United States from a position of dependence, but its progress in doing so is unclear. Current U.S. production still has not replaced our reliance on Russia and possibly other high-risk countries, and several proposed DOE facilities conceived as major contributors to the U.S. domestic supply chain remain in the design phase or, at best, under construction (chief among these is Oak Ridge’s Stable Isotope Production and Research Center, or SIPRC, which is reportedly not expected to start production until 2032). These dynamics raise serious questions and concerns about the security of the U.S. supply chain for these critical isotopes.” BACKGROUND: The DOE’s Isotope Program produces and sells hundreds of high priority isotopes that are rare—but essential—for the production of important commodities in national security, advanced manufacturing, and medicine.  The DOE is often the only, or one of very few, global producers of such isotopes, which are in short supply or represent a supply chain risk. However, the United States still relies on obtaining several materials and commercially produced isotopes from other, sometimes adversarial countries, such as Russia.  The GAO last reviewed the DOE Isotope program in 2012 and has not conducted a review since Russia invaded Ukraine in 2022.  According to a 2022 testimony by the executive director of the Council on Radionuclides and Radiopharmaceuticals, the U.S. still relies nearly exclusively on Russia to obtain 44 isotopes that are critical in industrial applications and cancer treatment.  China has also emerged as a new global supplier of stable isotopes, positioning the U.S. for even further foreign reliance to keep Americans healthy and safe. CLICK HERE to read the full letter.


Letters


Oct 21, 2024
Press Release

Bipartisan E&C Leaders Call on GAO to Review the DOE Isotope Program’s Work to Reduce Reliance on Russia

More than a decade has lapsed since the GAO’s last review Washington, D.C. —  In a new letter to the U.S. Government Accountability Office (GAO), bipartisan Energy and Commerce Leaders are requesting that the GAO conduct an extensive review of the Department of Energy’s (DOE) Isotope Program. Led by Committee Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr., (D-NJ) as well as Subcommittee on Energy, Climate, and Grid Security Chair Jeff Duncan (R-SC) and Ranking Member Diana DeGette (D-CO), the letter addresses concerns regarding U.S. dependence on Russia for isotopes and other materials critical to American national security, advanced manufacturing, and medicine, especially following Russia’s invasion of Ukraine. KEY LETTER EXCERPT: “The DOE Isotope Program has been working for at least a decade to shore up domestic isotope development and free the United States from a position of dependence, but its progress in doing so is unclear. Current U.S. production still has not replaced our reliance on Russia and possibly other high-risk countries, and several proposed DOE facilities conceived as major contributors to the U.S. domestic supply chain remain in the design phase or, at best, under construction (chief among these is Oak Ridge’s Stable Isotope Production and Research Center, or SIPRC, which is reportedly not expected to start production until 2032). These dynamics raise serious questions and concerns about the security of the U.S. supply chain for these critical isotopes.” BACKGROUND: The DOE’s Isotope Program produces and sells hundreds of high priority isotopes that are rare—but essential—for the production of important commodities in national security, advanced manufacturing, and medicine.  The DOE is often the only, or one of very few, global producers of such isotopes, which are in short supply or represent a supply chain risk. However, the United States still relies on obtaining several materials and commercially produced isotopes from other, sometimes adversarial countries, such as Russia.  The GAO last reviewed the DOE Isotope program in 2012 and has not conducted a review since Russia invaded Ukraine in 2022.  According to a 2022 testimony by the executive director of the Council on Radionuclides and Radiopharmaceuticals, the U.S. still relies nearly exclusively on Russia to obtain 44 isotopes that are critical in industrial applications and cancer treatment.  China has also emerged as a new global supplier of stable isotopes, positioning the U.S. for even further foreign reliance to keep Americans healthy and safe. CLICK HERE to read the full letter.



Oct 8, 2024
Press Release

Bipartisan E&C Leaders Request FDA Briefing for More Details about Counterfeit Ozempic

Washington, D.C. — In a letter today to Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., a bipartisan group of House Energy and Commerce Committee Leaders requested a briefing about the presence of counterfeit Ozempic and other semaglutide products in the United States’ medical supply chain.  The letter was signed by Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr. (D-NJ); Subcommittee on Health Chair Brett Guthrie (R-KY) and Ranking Member Anna G. Eshoo (D-CA); and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) and Ranking Member Kathy Castor (D-FL).   KEY LETTER QUOTE : “In addition to concerns about integrity gaps in the legitimate supply chain, we are also concerned about counterfeit Ozempic entering through illegal channels. For example, in June of this year, Eli Lilly issued an open letter expressing concern that counterfeit versions of its own drugs, Mounjaro and Zepbound, were being sold online, through social media and at medical spas. On May 1, 2024, a Department of Justice press release reported that work by FDA’s Office of Criminal Investigations resulted in the arrest of an individual for selling misbranded and adulterated weight loss drugs on TikTok. The Committee fully supports these continued investigations of unlawful sales.”   BACKGROUND :   The FDA alerted the public on December 21, 2023, to the presence of counterfeit Ozempic injection products in the legitimate drug supply; an investigati ve article l ater found that thousands of counterfeit Ozempic pens had arrived in a warehouse in Elmira, New York, as early as the fall of 2023. The fact that counterfeit medications made it into the legitimate medical supply chain raises concern about potential gaps in our supply chain security infrastructure.    This threat continues to grow.   CLICK HERE to read the full letter.



Oct 7, 2024
Letter

Chair Rodgers Leads House GOP in Demanding Answers Over FCC Fast-Tracking Democrat Mega-Donor’s Media Takeover Weeks Before Election

Soros-linked fund to acquire more than 200 local radio stations weeks before election Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) led 40 of her Republican colleagues in demanding answers from the Chairwoman of the Federal Communications Commission (FCC) regarding her recent decision to fast-track a media deal allowing the Fund for Policy Reform, a group aligned with Democratic mega-donor George Soros, to buy over 200 radio stations just weeks before the 2024 election. With a party line vote of 3-2, the decision at the Commission level by the Democratic members of the FCC to temporarily waive the required national security review and allow excessive foreign ownership of American radio stations is deeply disturbing. KEY LETTER EXCERPT: “It is highly concerning that the FCC did not follow regular order for a transaction of this magnitude. Licensees and investors need certainty that the FCC will follow its rules and procedures when approving transactions so that the broadcast industry can have the resources it needs to continue serving the public.”  BACKGROUND: Audacy, Inc., a radio broadcasting group, which owns more than 200 radio-station licenses, filed for bankruptcy earlier this year.  Audacy’s filings revealed that a George Soros-backed group known as the Fund for Policy Reform had acquired at least 40 percent of Audacy’s debt.   Audacy estimated that, upon emerging from bankruptcy, 25 percent or more of its stock would be indirectly foreign owned, which triggers FCC review.   This review process requires national security agencies to review the transaction and offer any policy or national security concerns.   On September 30, 2024, the FCC released an Order granting a temporary waiver of this review process, delaying a national security review until after the bankruptcy process is complete and allowing foreign control of a significant number of radio stations across the entire United States, weeks before a national election. CLICK HERE to read Breitbart's exclusive coverage. CLICK HERE to read the full letter.